In recent years, drug-industry executive Martin Shkreli and Mylan, the makers of EpiPen, garnered infamy for their pricing strategies. Yet consumers remain largely in the dark about drug pricing. Atlantic editor Steve Clemons questions a knowledgeable panel about the opaque math behind drug pricing – and then presses for better solutions. getAbstract recommends this elucidating and timely, yet frequently digressing, discussion.
In this summary, you will learn
- How drug companies decide drug prices,
- Why this pricing model fails consumers and other stakeholders, and
- How to improve the model.
About the Speakers
Henry Aaron is a senior fellow with the Brookings Institution, a public policy organization. Elizabeth Fowler is a global health policy executive for Johnson & Johnson. Gail Wilensky is a senior fellow with Project HOPE, a worldwide health foundation. Steve Clemons is editor of AtlanticLIVE, the events branch of The Atlantic magazine.
Comment on this summary
By the same authors
Scott Santens and Steve Clemons
The Atlantic, 2016
Customers who read this summary also read
Robert Langreth et al.
Jeff Elton and Anne O’Riordan
Anne Helen Petersen